Abstract: Objective :To observe the clinic response rate, time to progression(TTP), overall survival (OS) and the toxicity of PELF regimen for advanced gastric cancer. Methods : A total of 68 patients with advanced gastric adenocarcinoma, including 54 male and 14 female, were treated with PELF chemotherapy regimen. It comprised of Epirubicin, 50～80mg/m² intravenously (iv) bolus on day 1; Cisplatin 10～20mg/m2, iv, in 2-h infusion on days 1～5; leucovorin (LV) 100～200mg/m2, iv, in 2-h infusion on days 1～5; 5-Fu 500mg/m2, iv, in 4-h infusion on days 1～5; the cycles were repeated every 3～4 weeks and the first evaluation was done after two cycles. The median treatment cycle was 3.5 (ranged from 2 to 9). Results : Nineteen cases of gastric cancer in stage Ⅲ received adjuvant chemotherapy postoperation, 14 of them has been followed-up to date and still alive, and the 3-year survival rate was 52.9%. Fourty-eight patients were evaluable for response, which had 3 complete response (CR), 13 partial response (PR), 19 stable disease (SD), and 12 progression (PD). The overall response rate was 33.3%, the median TTP was 4.2 months, and the median OS was 10.2 months. All of the 68 patients were assessable for toxicity according to WHO standard. The incidence of grade Ⅲ～Ⅳ neutropenia, anemia, thromobocytopenia, vomiting and alopecia were 17.8%, 1.5%, 3.0%, 8.8% and 11.8%, respectively. Conclusion : PELF is an active and well tolerated regimen in treatment of advanced gastric cancer. Furthermore, it also meets the social and economic requirements in our country.